Nucleotide analogs as novel anti-hepatitis B virus agents
Current Opinions in Pharmacology
During the past decade, nucleotide analogs have emerged as novel antiviral agents against hepatitis B virus. Adefovir dipivoxil, a prototype phosphonate analog, has been approved for chronic hepatitis B virus therapy, and additional phosphonate analogs and di-and tri-nucleotides are under development. Several innovative prodrug derivatizations have also been reported to improve the oral bioavailability of nucleotide analogs, which usually carry a negative charge.
Radhakrishnan, P.I., S.P., G.Z., J.D. Morrey, and B.E. Korba 2005. Nucleotide analogs as novel anti-hepatitis B virus agents. Current Opinions in Pharmacology 5: 520-528.